Kayla Meritt, PhD student in Regulatory Biology
Undergraduate degree (Bachelors of Science in Biology) from: Cleveland State University, Cleveland, OH
Currently, PhD student in Regulatory Biology (the program is jointly operated with the Lerner Research Institute of the Cleveland Clinic). Undergoing rotation at the Lerner Research Institute of the Cleveland Clinic.
Personal statement: I am interested in cancer biology, specifically in how oncogenes play a significant role in chemotherapy resistance. As well, I intend to study the effect of chemotherapy drugs on leukemic and breast cancer patients and understand the mechanisms that govern metastatic development of cancer cells.
Kenya Wilcots, PhD student in Clinical-Bioanalytical Chemistry
Undergraduate degree (Bachelors of Science in Biology) from: Kentucky State University, Frankfort, KY
Currently, PhD student in Clinical-Bioanalytical Chemistry Program (jointly operated with the Lerner Research Institute of the Cleveland Clinic).
Personal statement: My research interest includes cancer biochemistry. With a focus on the development of new cancer approaches that will avoid damaging normal cells while stopping the proliferation of abnormal cancer cells. In doing so I will be working with Dr. Michael Kalafatis (Department of Chemistry, The Center for Gene Regulation in Health and Disease, CSU) exploring the apoptotic pathway and testing new drugs that trigger apoptosis in the intrinsic and extrinsic pathway.
Tanetta Curenton, Doctoral student in Applied Biomedical Engineering
Undergraduate degree (Bachelor of Arts) from: University of Pittsburgh, Pittsburgh, PA
Currently, PhD student in Applied Biomedical Engineering Program (jointly operated with the Lerner Research Institute of the Cleveland Clinic).
Personal statement: My research interests are at the interface of bioengineering and cancer cell biology. Focusing on molecular and cellular mechanisms, tissue engineering methods will be utilized to investigate and inform the development of novel therapeutic techniques and regenerative medicine approaches for brain cancer.
This material is based upon work supported by the National Science Foundation under Grant Numbers HRD 1432053, 1432864, 1432868, 1432878, 1432891, 1432921, and 1432950. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation.